NASDAQ:XERS Xeris Biopharma (XERS) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free XERS Stock Alerts $1.70 -0.06 (-3.41%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$1.70▼$1.7650-Day Range$1.70▼$3.2252-Week Range$1.46▼$3.26Volume893,739 shsAverage Volume2.13 million shsMarket Capitalization$238.77 millionP/E RatioN/ADividend YieldN/APrice Target$4.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Xeris Biopharma alerts: Email Address Xeris Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside186.8% Upside$4.88 Price TargetShort InterestBearish6.37% of Shares Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$9,720 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.38) to ($0.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.65 out of 5 starsMedical Sector255th out of 908 stocksPharmaceutical Preparations Industry103rd out of 421 stocks 3.5 Analyst's Opinion Consensus RatingXeris Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXeris Biopharma has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.37% of the outstanding shares of Xeris Biopharma have been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Xeris Biopharma has recently decreased by 0.45%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldXeris Biopharma does not currently pay a dividend.Dividend GrowthXeris Biopharma does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXeris Biopharma has received a 62.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pancreatic hormones (H04)" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Xeris Biopharma is -1.57. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 7 people have searched for XERS on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xeris Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,720.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.36% of the stock of Xeris Biopharma is held by insiders.Percentage Held by Institutions42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Xeris Biopharma are expected to grow in the coming year, from ($0.38) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xeris Biopharma is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xeris Biopharma is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Xeris Biopharma Stock (NASDAQ:XERS)Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.Read More XERS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XERS Stock News HeadlinesApril 5, 2024 | finance.yahoo.comXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutionsApril 3, 2024 | finance.yahoo.comXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 2, 2024 | finance.yahoo.comXeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 18, 2024 | proactiveinvestors.comXeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for 2024 GrowthMarch 9, 2024 | finance.yahoo.comHere's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual ResultsMarch 8, 2024 | seekingalpha.comXeris Biopharma (XERS) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comXeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023April 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.March 7, 2024 | insidermonkey.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comQ4 2023 Xeris Biopharma Holdings Inc Earnings CallMarch 6, 2024 | marketwatch.comXeris Biopharma Shares Drop After Weak 4Q ResultsMarch 6, 2024 | msn.comXeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84MMarch 6, 2024 | investorplace.comXERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023March 6, 2024 | proactiveinvestors.comXeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jumpMarch 6, 2024 | businesswire.comXeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent EventsMarch 6, 2024 | businesswire.comXeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin CapitalFebruary 28, 2024 | businesswire.comXeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024February 23, 2024 | theglobeandmail.com3 Breakout Stocks Under $5 to Buy for More UpsideFebruary 5, 2024 | finance.yahoo.comXeris to Present at the Oppenheimer 34th Annual Healthcare Life Science ConferenceFebruary 3, 2024 | realmoney.thestreet.comBig Game or Small, Here's How to Go About Stalking a TradeJanuary 10, 2024 | marketwatch.comXeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease TreatmentJanuary 10, 2024 | marketwatch.comXeris Biopharma Shares Climb 12% on Amgen License AgreementJanuary 10, 2024 | msn.comWhy Is Xeris Biopharma (XERS) Stock Up 12% Today?January 9, 2024 | seekingalpha.comXeris Biopharma: Speculative Buy, Size Your Position AccordinglyJanuary 4, 2024 | marketwatch.comXeris Biopharma Holdings Shares Jump 14% on Raised 2023 OutlookJanuary 4, 2024 | msn.comXeris Biopharma sees FY revenue at higher end of guidanceSee More Headlines Receive XERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/25/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XERS CUSIPN/A CIK1867096 Webwww.xerispharma.com Phone(844) 445-5704FaxN/AEmployees377Year FoundedN/APrice Target and Rating Average Stock Price Target$4.88 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside+186.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,260,000.00 Net Margins-37.98% Pretax Margin-38.74% Return on Equity-610.76% Return on Assets-19.15% Debt Debt-to-Equity Ratio49.27 Current Ratio1.64 Quick Ratio1.23 Sales & Book Value Annual Sales$163.91 million Price / Sales1.46 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-34.00Miscellaneous Outstanding Shares140,453,000Free Float134,329,000Market Cap$238.77 million OptionableOptionable Beta2.33 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Paul R. Edick (Age 68)Chairman & CEO Comp: $1.12MMr. John P. Shannon (Age 62)President & COO Comp: $827.72kMs. Beth P. Hecht J.D. (Age 60)Chief Legal Officer & Corporate Secretary Comp: $638.31kMr. Steven M. Pieper (Age 47)Chief Financial Officer Ms. Allison WeySenior Vice President of Investor Relations & Corporate CommunicationsDr. Kenneth E. Johnson Pharm. D. (Age 61)Pharm.D., Senior VP of Global Development & Medical Affairs Mr. Kevin McCullochChief Commercial OfficerMore ExecutivesKey CompetitorsXBiotechNASDAQ:XBITPuma BiotechnologyNASDAQ:PBYIVerastemNASDAQ:VSTMNektar TherapeuticsNASDAQ:NKTR23andMeNASDAQ:MEView All CompetitorsInsiders & InstitutionsRosalind Advisors Inc.Sold 723,515 shares on 4/25/2024Ownership: 2.008%Diversified Trust CoBought 20,091 shares on 4/18/2024Ownership: 0.125%Deltec Asset Management LLCSold 207,246 shares on 4/17/2024Ownership: 0.037%John P SchmidBought 4,500 shares on 3/14/2024Total: $9,720.00 ($2.16/share)Quarry LPBought 20,000 shares on 2/20/2024Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions XERS Stock Analysis - Frequently Asked Questions Should I buy or sell Xeris Biopharma stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XERS shares. View XERS analyst ratings or view top-rated stocks. What is Xeris Biopharma's stock price target for 2024? 4 Wall Street research analysts have issued twelve-month price targets for Xeris Biopharma's stock. Their XERS share price targets range from $4.00 to $6.00. On average, they anticipate the company's share price to reach $4.88 in the next twelve months. This suggests a possible upside of 186.8% from the stock's current price. View analysts price targets for XERS or view top-rated stocks among Wall Street analysts. How have XERS shares performed in 2024? Xeris Biopharma's stock was trading at $2.35 at the start of the year. Since then, XERS shares have decreased by 27.7% and is now trading at $1.70. View the best growth stocks for 2024 here. When is Xeris Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our XERS earnings forecast. How were Xeris Biopharma's earnings last quarter? Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) announced its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The business had revenue of $44.39 million for the quarter, compared to analyst estimates of $45.50 million. Xeris Biopharma had a negative net margin of 37.98% and a negative trailing twelve-month return on equity of 610.76%. During the same quarter in the prior year, the company posted ($0.10) earnings per share. What ETFs hold Xeris Biopharma's stock? ETFs with the largest weight of Xeris Biopharma (NASDAQ:XERS) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL). What guidance has Xeris Biopharma issued on next quarter's earnings? Xeris Biopharma issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $170.0 million-$200.0 million, compared to the consensus revenue estimate of $188.0 million. What other stocks do shareholders of Xeris Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and Organigram (OGI). When did Xeris Biopharma IPO? Xeris Biopharma (XERS) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager. Who are Xeris Biopharma's major shareholders? Xeris Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Rosalind Advisors Inc. (2.01%), Diversified Trust Co (0.13%) and Deltec Asset Management LLC (0.04%). Insiders that own company stock include Jeffrey W Sherman, John P Schmid, John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski. View institutional ownership trends. How do I buy shares of Xeris Biopharma? Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XERS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
